Highlighted Presentations

‍

10 December I 4 PM ET

Loss of OCT Outer Retinal Bands as Potential Clinical Trial Endpoints in Intermediate Age-Related Macular Degeneration

• Insights into the longitudinal change in the outer retinal bands (EZ, ELM, RPE), in a cohort with iAMD and their correlation with functional change

• Insight into the utility of these outer retinal bands as a potential clinical trial endpoint in iAMD interventional trials

• Clinical benefit of earlier intervention with nanolaser therapy in the LEAD trial, when assessing the loss of the outer retinal bands

‍

Professor Robyn Guymer AM, MBBS, PhD, FRANZCO, FAHMS

CERA Deputy Director, Head of Macula Research,
Prof. of Ophthalmology, Univ. of Melbourne

‍

‍

10 December I 4:20 PM ET

Fireside Chat with Retina Experts and RetinAI: Clinical endpoints in dry AMD and GA today and where we might be headed in the future. 

An interactive panel discussion from leaders in Retina and a member of RetinAI to provide perspectives on clinical endpoints for dry AMD and Geographic Atrophy today as well as potentially novel future endpoints.

• Understand the current state of clinical study endpoints that have been accepted by regulators.
• The role of technology in validating structural endpoints.
• The promise for evaluating outer retinal layers, including other structural biomarkers as future clinical study endpoints.
  ‍

Professor Robyn Guymer AM, MBBS, PhD, FRANZCO, FAHMS

CERA Deputy Director, Head of Macula Research,
Prof. of Ophthalmology, Univ. of Melbourne

‍

‍

‍Karl Csaky, MD, PhD

Chief Executive and Medical Officer, Retina Foundation of the Southwest

‍

‍Nataša Jovic, BSc., MBA ‍

Vice President Marketing Strategy & Research Partnerships, RetinAI

‍

‍

11 December I 1:30 PM ET

Data-Driven Discovery: The Role of AI & Emerging Tools in AMD disease prognosis

• Discussing how AI and machine learning models are applied differently in preclinical screening versus clinical endpoint prediction for dry AMD & geographic atrophy

• Comparing the utility and limitations of AI tools across stages of development, including variability in data sources, translational relevance, and regulatory acceptance

• Highlighting opportunities for AI to streamline the transition between discovery and development — enabling better target selection, patient stratification, and trial enrichment

‍

Omer Trivizki

Deputy Chair, Ophthalmology Division, Bascom Palmer Eye Institute

‍